Alkermes Plc (ALKS)

Healthcare · Drug Manufacturers - Specialty & Generic
$41.78 +0.30% on the day Market cap $6.7B 52-week range $27.00 to $55.67 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
0% a year for 10 years

At a market value of $6.7B, Alkermes Plc's free cash flow of $480M (fiscal 2025) would need to grow about 0% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 7 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Alkermes Plc's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price0.3% a year
Free cash flow, last 7 years48.7% a year
Revenue, same period7.9% a year
Price to free cash flow14.0x

Fundamental grade

C

Five factors scored 1 to 9 from ALKS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability4
Growth4
Financial health5
Cash efficiency9

Key numbers

P/E (trailing)44.7x
P/E (forward)98.5x
Price / free cash flow14.0x
EV / EBITDA34.2x
Price / sales4.02x
Price / book3.57x
Revenue growth+27.0%
Operating margin7.0%
Net margin4.0%
Return on equity3.7%
Dividend yield—
Debt / equity1.43x

Results from SEC filings

Fiscal years, from Alkermes Plc's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$1.2B$1.1B$1.7B$1.6B$1.5B
Net income-$48M-$158M$356M$367M$242M
Free cash flow$74M-$17M$353M$406M$480M
EPS (diluted)-$0.29-$0.97$2.10$2.17$1.43
Operating margin8.3%-0.55%24.9%27.0%17.2%

Where the revenue comes from

Revenue by products, fiscal 2025.

Product sales, net$1.2B80%
Manufacturing and royalty revenues$291M20%

Superinvestors who own ALKS

From each investor's latest 13F filing (what a 13F shows). 4 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
PRIMECAP Management
PRIMECAP Management Co
Trimmed $132M0.08%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $11M0.00%Q2 2026
Murray Stahl
Horizon Kinetics LLC
Trimmed $1M0.01%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed $584,5710.00%Q2 2026

Insider buying

Open-market purchases by Alkermes Plc's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of ALKS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when ALKS trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Alkermes Plc's stock price imply?

At a market value of $6.7B, Alkermes Plc would need its free cash flow to grow about 0% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 7 years its free cash flow grew 49% a year.

Are Alkermes Plc insiders buying the stock?

No open-market insider purchases of ALKS in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Alkermes Plc?

4 of the superinvestors Investingly tracks hold ALKS in their latest 13F, including PRIMECAP Management, Cliff Asness, Murray Stahl.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.